Amneal Pharmaceuticals, Inc. (AMRX) Earnings History
Earnings Pressure11 years of earnings data (2015–2025) · 5-year EPS trend is negative
Loading earnings history...
Amneal Pharmaceuticals, Inc. (AMRX) Earnings Overview
As of July 8, 2026, Amneal Pharmaceuticals, Inc. (AMRX) reported trailing twelve-month net income of $122M, reflecting +157.9% year-over-year growth. The company earned $0.37 per diluted share over the past four quarters, with a net profit margin of 2.4%.
Looking at the long-term picture, AMRX's 5-year EPS compound annual growth rate (CAGR) stands at -18.5%, signaling declining earnings. The company achieved its highest annual net income of $207M in fiscal 2016.
Amneal Pharmaceuticals, Inc. maintains positive profitability with a gross margin of 37.6%, operating margin of 14.0%, and net margin of 2.4%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including TEVA ($1.56B net income, 8.2% margin), VTRS (-$296M net income, -24.6% margin), PRGO (-$1.82B net income, -33.5% margin), AMRX has room to improve margins relative to the peer group. Compare AMRX vs TEVA →
AMRX Earnings vs Peers
Earnings metrics vs comparable public companies
AMRX Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $72M | +161.6% | $423M | $0.22 | 2.4% | 14.0% |
| 2024 | -$117M | -39.2% | $249M | $-0.38 | -4.2% | 8.9% |
| 2023 | -$84M | +35.4% | $204M | $-0.48 | -3.5% | 8.5% |
| 2022 | -$130M | -1323.5% | -$95M | $-0.86 | -5.9% | -4.3% |
| 2021 | $11M | -88.3% | $153M | $0.07 | 0.5% | 7.3% |
| 2020 | $91M | +125.2% | $91M | $0.61 | 4.6% | 4.6% |
| 2019 | -$362M | -113.2% | -$249M | $-4.57 | -22.3% | -15.3% |
| 2018 | -$170M | -201.2% | -$20M | $-1.33 | -10.2% | -1.2% |
| 2017 | $168M | -19.2% | $245M | $1.46 | 16.2% | 23.7% |
| 2016 | $207M | +22.4% | $285M | $1.10 | 20.4% | 28.0% |
| 2015 | $169M | - | $227M | $0.90 | 19.6% | 26.2% |
Download Data
Export AMRX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AMRX — Frequently Asked Questions
Quick answers to the most common questions about buying AMRX stock.
What is AMRX earnings per share (EPS)?
AMRX trailing twelve-month (TTM) diluted EPS is $0.37, reflecting +157.9% year-over-year growth. The 5-year EPS CAGR is -18.5%. Complete EPS history from 2015 to 2025 is available in the table on this page.
What is Amneal Pharmaceuticals, Inc.'s net income?
Amneal Pharmaceuticals, Inc. (AMRX) trailing twelve-month net income is $122M as of 2025. Earnings grew +157.9% year-over-year.
Is AMRX profitable?
Yes, AMRX is profitable with a TTM net income of $122M and a net profit margin of +2.4%.
What is AMRX's earnings growth rate?
AMRX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: -18.5%, 10-Year: -13.1%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.
What are AMRX's profit margins?
Amneal Pharmaceuticals, Inc. net profit margin is +2.4%, operating margin is +14.0%, and gross margin is +37.6%. Below-average margins reflect competitive or cost pressures. Return on Equity is +1208.4%.
Is AMRX growing earnings?
Yes, AMRX earnings are accelerating — EPS growth of +157.9% exceeds the 5-year CAGR of -18.5%. TTM net income reached $122M. Earnings momentum is strengthening.
What was AMRX's best earnings year?
Amneal Pharmaceuticals, Inc.'s highest annual net income on record is $207M, achieved in fiscal year 2016. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.
What were AMRX's earnings last quarter?
AMRX's most recent reported quarter was Q1 2026. Net income was $62M with diluted EPS of $0.19. For a full breakdown of all quarters, see the quarterly earnings table on this page.